Supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corporation
Welcome to the inaugural myCME TOWN WALL™. This unique platform allows you to hear from a wide variety of experts through an engaging visual display. The focus of this program is severe asthma.
Given the chronic and inflammatory nature of asthma, many patients with asthma have persistent daily symptoms and exacerbations despite compliance with high doses of inhaled steroids, long-acting beta-agonists, and other supplemental therapies. Factors that play a role in poor asthma control include clinician lack of awareness of current treatment guidelines and a failure to use validated tools to assess severity; different perceptions or definitions of control between the patient and the clinician; lack of adherence to therapy; poor inhaler technique and inadequate dosing; and patient misconceptions regarding specific agents. In light of these challenges, respiratory specialists and primary care providers should become familiar with inflammatory mediators such as immunoglobulin E (IgE), interleukin-5 (IL-5), and IL-13, along with recently approved asthma therapies that address the pathophysiologic abnormalities associated with moderate to severe, often hard-to-treat asthma. For such patients, there is a need to integrate into practice contemporary approaches to asthma management that are aligned with published guidelines and accepted standards of care. Healthcare providers also should work in concert with patients in the selection of therapies and of the most appropriate delivery device to foster improved adherence and overall outcomes.
The proposed activity is designed for allergists/immunologists, pulmonologists, and primary care clinicians (family medicine and internal medicine [IM] physicians, nurse practitioners [NPs], and physician assistants [PAs]).
After completing the activity, the participant should be better able to:
Evaluate the role of inflammatory mediators and other abnormalities in the pathogenesis of asthma
Apply evidence-based guidelines to individualized treatment plans for patients with asthma
Develop collaborative treatment strategies and a stronger provider-patient partnership to ensure optimal control of moderate to severe asthma
Analyze the safety and efficacy of new and emerging agents for the management of poorly controlled asthma
Conflict Of Interest Disclosure Policies
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Peter Salgo, MD Professor of Medicine and Anesthesiology Columbia University College of Physicians and Surgeons Associate Director Surgical Intensive Care Columbia University Medical Center New York, NY
Dr. Salgo has no relevant financial relationships to disclose.
Michael S. Blaiss, MD, FACAAI Clinical Professor of Pediatrics Medical College of Georgia at Augusta University Augusta, GA
Dr. Blaiss is a consultant for ALK, Bayer, Boston Scientific, Hycor BioMedical, Pfizer Inc., PMD Healthcare, Regeneron, Sanofi, and Stallergenes Greer.
Nicola Hanania, MD, MS Associate Professor of Medicine Director, Airways Clinical Research Center Baylor College of Medicine Houston, TX
Dr. Hanania is a consultant for AstraZeneca, Boehringer lngelheim, GSK, Novartis, and Sanofi/Regeneron and is an investigator for AstraZeneca, Boehringer lngelheim, Genentech, and GSK.
Eli O. Meltzer, MD Department of Pediatrics Division of Allergy and Immunology University of California Allergy & Asthma Medical Group and Research Center San Diego, CA
Dr. Meltzer is a consultant for ALK Inc., Allergan, AstraZeneca, GSK, Glenmark, and Regeneron/Sanofi; is on the speakers’ bureaus for ALK, Mylan, and Stallergenes Greer; and is an investigator for HealthLogiX.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
ANCILLARY FACULTY PRESENTERS
Ingrid Cantrell, PA Allergy & Asthma Care Germantown, TN
Ms. Cantrell has no relevant financial relationships to disclose.
Dharani Kumari Narendra, MD Assistant Professor of Medicine Pulmonary, Critical Care, and Sleep Section Baylor College of Medicine Houston, TX
Dr. Narendra has no relevant financial relationships to disclose.
Amit Parulekar, MD, MS Assistant Professor of Medicine Section of Pulmonary, Critical Care, and Sleep Medicine Baylor College of Medicine Houston, TX
Dr. Parulekar has no relevant financial relationships to disclose.
Michael J. Welch, MD, FAAP, FAAAAI Co-director, Allergy & Asthma Medical Group and Research Center Clinical Professor University of California at San Diego School of Medicine San Diego, CA
Dr. Welch has no relevant financial relationships to disclose.
Ari Zelig, MD Allergy Associates of Sarasota and Venice Sarasota, FL
Dr. Zelig has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, AstraZeneca, or Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you have any questions relating to the accreditation of this activity, please contact Haymarket Medical Education.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.